Aslan Pharmaceuticals Newsroom

Piper Sandler Remains a Buy on Aslan Pharmaceuticals (ASLN)

TipRanksMay 10 08:10 ET

ASLAN Pharma Analyst Ratings

BenzingaMay 3 15:17 ET

Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF) and Aslan Pharmaceuticals (ASLN)

TipRanksMay 3 08:35 ET

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)

TipRanksApr 23 06:25 ET

ASLAN Pharma Analyst Ratings

BenzingaApr 23 06:17 ET

ASLAN Pharma Analyst Ratings

BenzingaApr 15 08:04 ET

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)

TipRanksApr 15 06:25 ET

ASLAN Pharma Analyst Ratings

BenzingaMar 18 07:05 ET

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)

TipRanksMar 18 06:35 ET

ASLAN Pharma Analyst Ratings

BenzingaMar 13 07:47 ET

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Legend Biotech (LEGN) and Aslan Pharmaceuticals (ASLN)

TipRanksMar 13 07:06 ET

ASLAN Pharma Analyst Ratings

BenzingaMar 11 15:00 ET

HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $17 Price Target

BenzingaNov 6, 2023 06:47 ET

ASLAN Pharma Analyst Ratings

BenzingaNov 6, 2023 06:43 ET

Promising Drug Development Progress Boosts Aslan Pharmaceuticals' Buy Rating: An Analysis of Eblasakimab's Potential in Treating AD and COPD

TipRanksNov 6, 2023 06:28 ET

Piper Sandler Reaffirms Their Buy Rating on Aslan Pharmaceuticals (ASLN)

TipRanksOct 30, 2023 06:56 ET

Aslan Pharmaceuticals: Promising Financial Results and Optimistic Drug Trial Outcomes Boost Buy Rating

TipRanksOct 30, 2023 06:27 ET

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Prime Medicine, Inc. (PRME) and HealthStream (HSTM)

TipRanksOct 25, 2023 07:30 ET

ASLAN Pharma Analyst Ratings

BenzingaAug 14, 2023 06:36 ET

HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $17 Price Target

BenzingaJul 7, 2023 12:16 ET